About Corimmun
Corimmun is a company based in Planegg (Germany) founded in 2006 was acquired by Janssen Pharmaceutica in June 2012.. Corimmun has raised $18.47 million across 3 funding rounds from investors including Johnson & Johnson Innovative Medicine, KfW and BioM. Corimmun operates in a competitive market with competitors including Tenaya Therapeutics, Cellino, MyoKardia, Eiger BioPharmaceuticals and Arrakis Therapeutics, among others.
- Headquarter Planegg, Germany
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
- Legal Name Corimmun Gmbh
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$18.47 M (USD)
in 3 rounds
-
Latest Funding Round
$10.39 M (USD), Series B
Oct 31, 2010
- Investors
-
Employee Count
Employee Count
-
Acquired by
Janssen Pharmaceutica
(Jun 28, 2012)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Corimmun
Corimmun has successfully raised a total of $18.47M across 3 strategic funding rounds. The most recent funding activity was a Series B round of $10.39 million completed in October 2010. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 3
- Last Round Series B — $10.4M
-
First Round
First Round
(01 Jun 2007)
- Investors Count 5
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct, 2010 | Amount | Series B - Corimmun | Valuation | MIG Capital | |
| Sep, 2008 | Amount | Series A - Corimmun | Valuation | MIG Capital | |
| Jun, 2007 | Amount | Seed - Corimmun | Valuation | Bayern Kapital , BioM |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Corimmun
Corimmun has secured backing from 6 investors, including venture fund and institutional investors. Prominent investors backing the company include Johnson & Johnson Innovative Medicine, KfW and BioM. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
VC Firm funding companies in Europe
|
Founded Year | Domain | Location | |
|
High-tech industries are targeted for investments by Bayern Kapital.
|
Founded Year | Domain | Location | |
|
Early-stage investments are made in high-tech startups by HTGF.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Corimmun
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Corimmun
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Corimmun Comparisons
Competitors of Corimmun
Corimmun operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Tenaya Therapeutics, Cellino, MyoKardia, Eiger BioPharmaceuticals and Arrakis Therapeutics, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Regenerative and gene therapeutics for heart failure are developed.
|
|
| domain | founded_year | HQ Location |
Developer of autologous cell therapies
|
|
| domain | founded_year | HQ Location |
Specialized drugs are developed for genetic heart diseases.
|
|
| domain | founded_year | HQ Location |
Developer of antiviral agents against targets in the treatment of hepatitis
|
|
| domain | founded_year | HQ Location |
Provider of tools for the analysis of RNA structures
|
|
| domain | founded_year | HQ Location |
Regenerative medicine for cardiovascular disorders is developed using cell-based platforms.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Frequently Asked Questions about Corimmun
When was Corimmun founded?
Corimmun was founded in 2006 and raised its 1st funding round 1 year after it was founded.
Where is Corimmun located?
Corimmun is headquartered in Planegg, Germany. It is registered at Planegg, Bavaria, Germany.
Is Corimmun a funded company?
Corimmun is a funded company, having raised a total of $18.47M across 3 funding rounds to date. The company's 1st funding round was a Seed of $855K, raised on Jun 01, 2007.
What does Corimmun do?
Corimmun is a clinical drug development company focused on novel therapeutics and diagnostics for heart and vascular diseases. Acquired by Janssen pharmaceuticals in June 2012. The companys lead compound, COR-1, is a small cyclic peptide for the treatment of heart failure and COR-2, a soluble recombinant therapeutic protein that prevents foam cell formation in atherosclerotic plaques. Also provides ELISA-based assay development services for the detection of drugs or other agents, and for antibody detection in blood samples or other liquids, as well as for pharmacokinetic studies or antibody determinations in human or animal blood samples.
Who are the top competitors of Corimmun?
Corimmun's top competitors include Esperion Therapeutics, Tenaya Therapeutics and Cellino.
Who are Corimmun's investors?
Corimmun has 6 investors. Key investors include Johnson & Johnson Innovative Medicine, KfW, BioM, MIG Capital, and Bayern Kapital.